BPC-157 targets localised tissue repair — accelerating collagen synthesis and angiogenesis at the site of injury. TB-500 provides complementary systemic healing by regulating actin dynamics and reducing inflammation body-wide. Research consistently demonstrates synergistic outcomes when both are co-administered in musculoskeletal injury models.

BPC-157 drives cellular repair and promotes blood vessel growth, while GHK-Cu stimulates collagen and elastin synthesis and activates matrix remodelling enzymes. Together they address both the structural and regenerative aspects of tissue healing — an evidence-based combination for wound healing and connective tissue research.

Ipamorelin acts on the GHSR-1a receptor to produce selective GH pulses, while Tesamorelin stimulates the pituitary via the GHRH receptor. The dual-pathway approach maximises GH axis stimulation without the cortisol or prolactin elevation associated with earlier secretagogues, making this the most studied GH research stack available.

Tirzepatide provides dual GIP/GLP-1 receptor agonism for appetite suppression and insulin sensitisation. Retatrutide adds glucagon receptor activation, driving additional thermogenesis and hepatic fat mobilisation. Research data shows this combination targets metabolic dysfunction through three independent but complementary mechanisms.

NAD+ replenishes the cellular coenzyme critical for sirtuin activation and DNA repair — processes that decline with age. GHK-Cu simultaneously upregulates over 4,000 genes associated with tissue remodelling and antioxidant defence. Together they address multiple hallmarks of cellular ageing in a single research protocol.